APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adrenoleukodystrophy Drugs

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

Selected research

Industry Growth & Trends

Global Adrenoleukodystrophy Drugs Industry Growth and Trends Forecast to 2032

26 December 202598 pages

Choose your research edition.

Industry ResearchAdrenoleukodystrophy Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Adrenoleukodystrophy Drugs Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Adrenoleukodystrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adrenoleukodystrophy Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Adrenoleukodystrophy Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

Read the full market overview

By region, North America has the highest share of revenue, exceeding 60 percent in 2019.

Report Scope

This report provides a structured, data-driven view of the global Adrenoleukodystrophy Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Adrenoleukodystrophy Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Adrenoleukodystrophy Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Adrenoleukodystrophy Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Adrenoleukodystrophy Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Adrenoleukodystrophy Drugs Market by Company

Bluebird Bio Inc

NeuroVia, Inc.

Orpheris, Inc.

Minoryx

MedDay Pharmaceuticals

Adrenoleukodystrophy Drugs Segment by Type

Hormone Replacement

Transplant

Others

Adrenoleukodystrophy Drugs Segment by Application

Childhood Cerebral ALD

Adrenomyeloneuropathy (AMN)

Addison-only

Others

Adrenoleukodystrophy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adrenoleukodystrophy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adrenoleukodystrophy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adrenoleukodystrophy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Adrenoleukodystrophy Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Adrenoleukodystrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Hormone Replacement Table 2. Major Company of Transplant Table 3. Major Company of Others Table 4. Global Adrenoleukodystrophy Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (K Units) Table 6. Global Adrenoleukodystrophy Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Adrenoleukodystrophy Drugs Price by Type (2021-2026) & (US$/Unit) Table 10. Global Adrenoleukodystrophy Drugs Sales by Type (2027-2032) & (K Units) Table 11. Global Adrenoleukodystrophy Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Adrenoleukodystrophy Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Adrenoleukodystrophy Drugs Price by Type (2027-2032) & (US$/Unit) Table 15. North America Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (K Units) Table 16. North America Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (K Units) Table 18. Europe Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (K Units) Table 22. Latin America Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Adrenoleukodystrophy Drugs Industry Trends Table 26. Adrenoleukodystrophy Drugs Industry Drivers Table 27. Adrenoleukodystrophy Drugs Industry Opportunities and Challenges Table 28. Adrenoleukodystrophy Drugs Industry Restraints Table 29. Global Adrenoleukodystrophy Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Adrenoleukodystrophy Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Adrenoleukodystrophy Drugs Sales by Company (2021-2026) & (K Units) Table 32. Global Adrenoleukodystrophy Drugs Sales Share by Company (2021-2026) Table 33. Global Adrenoleukodystrophy Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Adrenoleukodystrophy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Adrenoleukodystrophy Drugs Major Company Production Sites and Headquarters Table 36. Global Adrenoleukodystrophy Drugs Company, Product Type & Application Table 37. Global Adrenoleukodystrophy Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Adrenoleukodystrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Adrenoleukodystrophy Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Adrenoleukodystrophy Drugs Sales by Region (2021-2026) & (K Units) Table 42. Global Adrenoleukodystrophy Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Adrenoleukodystrophy Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Adrenoleukodystrophy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Adrenoleukodystrophy Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Adrenoleukodystrophy Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Adrenoleukodystrophy Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Adrenoleukodystrophy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Adrenoleukodystrophy Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (K Units) Table 53. Global Adrenoleukodystrophy Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Adrenoleukodystrophy Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Adrenoleukodystrophy Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global Adrenoleukodystrophy Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Adrenoleukodystrophy Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Adrenoleukodystrophy Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Adrenoleukodystrophy Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. North America Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (K Units) Table 63. North America Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (K Units) Table 65. Europe Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (K Units) Table 69. Latin America Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Bluebird Bio Inc Company Information Table 73. Bluebird Bio Inc Business Overview Table 74. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Portfolio Table 76. Bluebird Bio Inc Recent Development Table 77. NeuroVia, Inc. Company Information Table 78. NeuroVia, Inc. Business Overview Table 79. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Portfolio Table 81. NeuroVia, Inc. Recent Development Table 82. Orpheris, Inc. Company Information Table 83. Orpheris, Inc. Business Overview Table 84. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Portfolio Table 86. Orpheris, Inc. Recent Development Table 87. Minoryx Company Information Table 88. Minoryx Business Overview Table 89. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Minoryx Adrenoleukodystrophy Drugs Product Portfolio Table 91. Minoryx Recent Development Table 92. MedDay Pharmaceuticals Company Information Table 93. MedDay Pharmaceuticals Business Overview Table 94. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Portfolio Table 96. MedDay Pharmaceuticals Recent Development Table 97. North America Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 98. North America Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 99. North America Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2026) Table 100. North America Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 101. North America Adrenoleukodystrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 102. North America Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 103. North America Adrenoleukodystrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 104. North America Adrenoleukodystrophy Drugs Market Share by Country (2021-2026) Table 105. North America Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 106. North America Adrenoleukodystrophy Drugs Market Share Forecast by Country (2027-2032) Table 107. Europe Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 108. Europe Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 109. Europe Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2026) Table 110. Europe Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 111. Europe Adrenoleukodystrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 112. Europe Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. Europe Adrenoleukodystrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 114. Europe Adrenoleukodystrophy Drugs Market Share by Country (2021-2026) Table 115. Europe Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. Europe Adrenoleukodystrophy Drugs Market Share Forecast by Country (2027-2032) Table 117. Asia-Pacific Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 118. Asia-Pacific Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 119. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2026) Table 120. Asia-Pacific Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 121. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 124. Asia-Pacific Adrenoleukodystrophy Drugs Market Share by Country (2021-2026) Table 125. Asia-Pacific Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Asia-Pacific Adrenoleukodystrophy Drugs Market Share Forecast by Country (2027-2032) Table 127. Latin America Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. Latin America Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 129. Latin America Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2026) Table 130. Latin America Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 131. Latin America Adrenoleukodystrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 132. Latin America Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Latin America Adrenoleukodystrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 134. Latin America Adrenoleukodystrophy Drugs Market Share by Country (2021-2026) Table 135. Latin America Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Latin America Adrenoleukodystrophy Drugs Market Share Forecast by Country (2027-2032) Table 137. Middle East and Africa Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 139. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2026) Table 140. Middle East and Africa Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 141. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. Middle East and Africa Adrenoleukodystrophy Drugs Market Share by Country (2021-2026) Table 145. Middle East and Africa Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Middle East and Africa Adrenoleukodystrophy Drugs Market Share Forecast by Country (2027-2032) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Adrenoleukodystrophy Drugs Distributors List Table 150. Adrenoleukodystrophy Drugs Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Adrenoleukodystrophy Drugs Image Figure 2. Global Adrenoleukodystrophy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adrenoleukodystrophy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Adrenoleukodystrophy Drugs Sales (2021-2032) & (K Units) Figure 5. Hormone Replacement Image Figure 6. Global Hormone Replacement Sales YoY Growth (2021-2032) & (K Units) Figure 7. Transplant Image Figure 8. Global Transplant Sales YoY Growth (2021-2032) & (K Units) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Adrenoleukodystrophy Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Adrenoleukodystrophy Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Adrenoleukodystrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Adrenoleukodystrophy Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Adrenoleukodystrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Adrenoleukodystrophy Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Adrenoleukodystrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Adrenoleukodystrophy Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Adrenoleukodystrophy Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Childhood Cerebral ALD Image Figure 26. Global Childhood Cerebral ALD Sales YoY Growth (2021-2032) & (K Units) Figure 27. Adrenomyeloneuropathy (AMN) Image Figure 28. Global Adrenomyeloneuropathy (AMN) Sales YoY Growth (2021-2032) & (K Units) Figure 29. Addison-only Image Figure 30. Global Addison-only Sales YoY Growth (2021-2032) & (K Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Adrenoleukodystrophy Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Adrenoleukodystrophy Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Adrenoleukodystrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Adrenoleukodystrophy Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Adrenoleukodystrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Adrenoleukodystrophy Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Adrenoleukodystrophy Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Adrenoleukodystrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Adrenoleukodystrophy Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Adrenoleukodystrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Adrenoleukodystrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Adrenoleukodystrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Adrenoleukodystrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Adrenoleukodystrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Adrenoleukodystrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Adrenoleukodystrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Adrenoleukodystrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Adrenoleukodystrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Adrenoleukodystrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Adrenoleukodystrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Adrenoleukodystrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Adrenoleukodystrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Adrenoleukodystrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Adrenoleukodystrophy Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Adrenoleukodystrophy Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Hormone Replacement
  • Transplant
  • Others
Applications
  • Childhood Cerebral ALD
  • Adrenomyeloneuropathy (AMN)
  • Addison-only
  • Others
Companies covered
  • Bluebird Bio Inc
  • NeuroVia, Inc.
  • Orpheris, Inc.
  • Minoryx
  • MedDay Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Adrenoleukodystrophy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Adrenoleukodystrophy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Adrenoleukodystrophy Drugs Market by Type
  6. 1.3.1 Hormone Replacement
  7. 1.3.2 Transplant
  8. 1.3.3 Others
  9. 1.4 Global Adrenoleukodystrophy Drugs Market Size by Type
  10. 1.4.1 Global Adrenoleukodystrophy Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Adrenoleukodystrophy Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Adrenoleukodystrophy Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Adrenoleukodystrophy Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Adrenoleukodystrophy Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Adrenoleukodystrophy Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Adrenoleukodystrophy Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Adrenoleukodystrophy Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Adrenoleukodystrophy Drugs Industry Trends
  2. 2.2 Adrenoleukodystrophy Drugs Industry Drivers
  3. 2.3 Adrenoleukodystrophy Drugs Industry Opportunities and Challenges
  4. 2.4 Adrenoleukodystrophy Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Adrenoleukodystrophy Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Adrenoleukodystrophy Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Adrenoleukodystrophy Drugs Price (2021-2026)
  4. 3.4 Global Adrenoleukodystrophy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Adrenoleukodystrophy Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Adrenoleukodystrophy Drugs Company, Product Type & Application
  7. 3.7 Global Adrenoleukodystrophy Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Adrenoleukodystrophy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Adrenoleukodystrophy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Adrenoleukodystrophy Drugs Tier 1, Tier 2, and Tier 3
4 Adrenoleukodystrophy Drugs Regional Status and Outlook
  1. 4.1 Global Adrenoleukodystrophy Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Adrenoleukodystrophy Drugs Historic Market Size by Region
  3. 4.2.1 Global Adrenoleukodystrophy Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Adrenoleukodystrophy Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Adrenoleukodystrophy Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Adrenoleukodystrophy Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Adrenoleukodystrophy Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Adrenoleukodystrophy Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Adrenoleukodystrophy Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Adrenoleukodystrophy Drugs by Application
  1. 5.1 Adrenoleukodystrophy Drugs Market by Application
  2. 5.1.1 Childhood Cerebral ALD
  3. 5.1.2 Adrenomyeloneuropathy (AMN)
  4. 5.1.3 Addison-only
  5. 5.1.4 Others
  6. 5.2 Global Adrenoleukodystrophy Drugs Market Size by Application
  7. 5.2.1 Global Adrenoleukodystrophy Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Adrenoleukodystrophy Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Adrenoleukodystrophy Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Adrenoleukodystrophy Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Adrenoleukodystrophy Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Adrenoleukodystrophy Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Adrenoleukodystrophy Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Adrenoleukodystrophy Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bluebird Bio Inc
  2. 6.1.1 Bluebird Bio Inc Company Information
  3. 6.1.2 Bluebird Bio Inc Business Overview
  4. 6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Portfolio
  6. 6.1.5 Bluebird Bio Inc Recent Developments
  7. 6.2 NeuroVia, Inc.
  8. 6.2.1 NeuroVia, Inc. Company Information
  9. 6.2.2 NeuroVia, Inc. Business Overview
  10. 6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Portfolio
  12. 6.2.5 NeuroVia, Inc. Recent Developments
  13. 6.3 Orpheris, Inc.
  14. 6.3.1 Orpheris, Inc. Company Information
  15. 6.3.2 Orpheris, Inc. Business Overview
  16. 6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Product Portfolio
  18. 6.3.5 Orpheris, Inc. Recent Developments
  19. 6.4 Minoryx
  20. 6.4.1 Minoryx Company Information
  21. 6.4.2 Minoryx Business Overview
  22. 6.4.3 Minoryx Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Minoryx Adrenoleukodystrophy Drugs Product Portfolio
  24. 6.4.5 Minoryx Recent Developments
  25. 6.5 MedDay Pharmaceuticals
  26. 6.5.1 MedDay Pharmaceuticals Company Information
  27. 6.5.2 MedDay Pharmaceuticals Business Overview
  28. 6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Portfolio
  30. 6.5.5 MedDay Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Adrenoleukodystrophy Drugs Sales by Country
  2. 7.1.1 North America Adrenoleukodystrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Adrenoleukodystrophy Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Adrenoleukodystrophy Drugs Market Size by Country
  6. 7.2.1 North America Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Adrenoleukodystrophy Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Adrenoleukodystrophy Drugs Sales by Country
  2. 8.1.1 Europe Adrenoleukodystrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Adrenoleukodystrophy Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Adrenoleukodystrophy Drugs Market Size by Country
  6. 8.2.1 Europe Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Adrenoleukodystrophy Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Adrenoleukodystrophy Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Adrenoleukodystrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Adrenoleukodystrophy Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Adrenoleukodystrophy Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Adrenoleukodystrophy Drugs Sales by Country
  2. 10.1.1 South America Adrenoleukodystrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Adrenoleukodystrophy Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Adrenoleukodystrophy Drugs Market Size by Country
  6. 10.2.1 South America Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Adrenoleukodystrophy Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Adrenoleukodystrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Adrenoleukodystrophy Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Adrenoleukodystrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Adrenoleukodystrophy Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Adrenoleukodystrophy Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Adrenoleukodystrophy Drugs Value Chain Analysis
  2. 12.1.1 Adrenoleukodystrophy Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Adrenoleukodystrophy Drugs Production Mode & Process
  7. 12.2 Adrenoleukodystrophy Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Adrenoleukodystrophy Drugs Distributors
  10. 12.2.3 Adrenoleukodystrophy Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst